Celyad Oncology Names Company Insider Georges Rawadi as New CEO Effective March 23

3/24/23 3:44:17 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CYAD alert in real time by email

Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased to announce Georges Rawadi as its new Chief Executive Officer (CEO), effective as of March 23, 2023, with starting date April 17, 2023. Michel Lussier will continue to serve as Interim CEO until April 17 to facilitate transition.

Get the next $CYAD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CYAD

Date	Price Target	Rating	Analyst
1/11/2022	$20.00 → $11.00	Overweight	Wells Fargo
8/6/2021	$17.00 → $15.00	Buy	HC Wainwright & Co.

More analyst ratings

Celyad Oncology reports full year 2022 financial results and recent business highlights
Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via (i) strengthening of its research focus centered around NKG2D, B7-H6 and shRNA platforms; (ii) maximizing the value of its IP estate and (iii) driving innovation through strategic collaborations. MONT-SAINT-GUIBERT, Belgium, March 23, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announces its financial results for the fiscal year 2022 e
3/23/23 5:01:00 PM ET
$CYAD
Biotechnology: Pharmaceutical Preparations
Health Care
Celyad Oncology to announce full year 2022 financial results and host conference call
MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that the Company will report full year 2022 financial and operating results on the evening of Thursday, March 23rd. Following the press release, the Company management will host a conference call on Friday, March 24th 2023 at 1 p.m. CET / 8 a.m. ET to discuss full year 2022 results and provide an update on the Company's recent changes and upcoming milestones. Participants may access the conference call by d
3/17/23 5:01:00 PM ET
$CYAD
Biotechnology: Pharmaceutical Preparations
Health Care
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM)In July 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical hold for the T-cell-inhibitory-molecule (TIM)-based allogeneic CAR T candidate CYAD-101 for metastatic colorectal cancer (mCRC)Company to increase strategic focus on collaborations related to broad intellectual property portfolioConference call and webcast scheduled for today, August 5th, at 2:00 p.m. CEST / 8:00 a.m. EDT MONT-SAINT-GUIBERT, Belgium, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Com
8/5/22 1:00:00 AM ET
$CYAD
Biotechnology: Pharmaceutical Preparations
Health Care

Celyad Oncology announces receipt of Nasdaq delisting notice
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced on April 4th, 2023, that The Nasdaq Stock Market ("Nasdaq") notified the Company on March 31st, 2023 that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company's stockholders' equity be at least $10.0 million. Further, on April 19th, 2023, as announced by the Company on April 24th, 2023, the Company received a n
5/15/23 4:01:00 PM ET
$CYAD
Biotechnology: Pharmaceutical Preparations
Health Care
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that its Board of Directors has approved the voluntary delisting of its American Depositary Shares representing ordinary shares ("ADSs") from the Nasdaq Global Market, termination of its American Depositary Receipt ("ADR") facility and deregistration with the U.S. Securities and Exchange Commission (the "SEC") upon satisfaction of the requirements for deregistration. The Company will continue to be listed on Euronext Brussels. In connection w
5/5/23 1:00:00 AM ET
$CYAD
Biotechnology: Pharmaceutical Preparations
Health Care
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneouslyPublication of results from the THINK trial, which provided proof-of-concept of our NKG2D-based CAR T-cell approach MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today reports its financial results for the first quarter of 2023 and provides an update on recent business developments. "Celyad Oncology is now fully committed to leveraging its expertise, know-how and intellectual p
5/5/23 1:00:00 AM ET
$CYAD
Biotechnology: Pharmaceutical Preparations
Health Care

$CYAD
Leadership Updates

Live Leadership Updates

Celyad Oncology appoints Georges Rawadi as its new CEO
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased to announce Georges Rawadi as its new Chief Executive Officer (CEO), effective as of March 23, 2023, with starting date April 17, 2023. Michel Lussier will continue to serve as Interim CEO until April 17 to facilitate transition. Georges Rawadi is a seasoned executive with over 20 years of experience in pharma/biotech, as research director, business developer, CEO and board member. He spent four years at Celyad Oncology (2014-2018) as Vice-Presi
3/24/23 2:00:00 AM ET
$CYAD
Biotechnology: Pharmaceutical Preparations
Health Care
Celyad Oncology Announces Leadership Updates
MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Board of Directors has named Hilde Windels as Chairwoman of the Board of Directors, effective immediately. Ms. Windels has been a member of the Board of Directors since May 2018. Ms. Windels serves on multiple boards in the life sciences industry and has been an executive in the sector from 1999 through 2021, serving primarily as Chief Financial Officer and, over the last five years, as Chief Execu
6/24/22 1:05:00 AM ET
$CYAD
Biotechnology: Pharmaceutical Preparations
Health Care
Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights
Enrollment continues in second dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM); additional proof-of-concept data anticipated in second quarter 2021.Expansion segment of Phase 1 alloSHRINK trial evaluating allogeneic CYAD-101 administered concurrently with preconditioning chemotherapy for the treatment of advanced metastatic colorectal cancer (mCRC) ongoing; preliminary data expected in mid-2021.Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 with KEYTRUDA® in patients with microsatellite stable mCRC expected to be initiated in first half of 2021. MONT-SAINT-GUIBERT, Belgiu
5/6/21 4:01:00 PM ET
$CYAD
Biotechnology: Pharmaceutical Preparations
Health Care

$CYAD
Market Insights

Live Market Insights

Celyad Oncology Announces Receipt Of Nasdaq Delisting Notice
Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced on April 4th, 2023, that The Nasdaq Stock Market ("Nasdaq") notified the Company on March 31st, 2023 that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company's stockholders' equity be at least $10.0 million. Further, on April 19th, 2023, as announced by the Company on April 24th, 2023, the Company received a notice from Nasdaq informing the Company that the minimum closi
5/15/23 4:30:27 PM ET
$CYAD
Biotechnology: Pharmaceutical Preparations
Health Care
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Nanobiotix (NASDAQ:NBTX) stock increased by 125.6% to $4.58 during Friday's pre-market session. The company's market cap stands at $161.3 million. Star Equity Hldgs (NASDAQ:STRR) stock moved upwards by 24.63% to $0.86. The company's market cap stands at $13.0 million. Aditxt (NASDAQ:ADTX) stock rose 19.94% to $0.79. The market value of their outstanding shares is at $4.0 million. Telesis Bio (NASDAQ:TBIO) shares moved upwards by 17.81% to $3.24. The company's market cap stands at $96.0 million. Fulgent Genetics (NASDAQ:FLGT) stock increased by 15.7% to $33.0. The company's market cap stands at $979.8 million. The company's, Q1 earnings came out today. Owens & Minor (NYSE:OMI) s
5/5/23 9:06:43 AM ET
$ADTX
$AKLI
$BIOL
$CANF
Biotechnology: Pharmaceutical Preparations
Health Care
Medical/Dental Instruments
Medical Specialities
Celyad Oncology Has Approved Voluntary Delisting Of American Depositary Shares From NASDAQ, The Company Will Continue To Be Listed On Euronext Brussels
5/5/23 4:05:15 AM ET
$CYAD
Biotechnology: Pharmaceutical Preparations
Health Care

Celyad Oncology Names Company Insider Georges Rawadi as New CEO Effective March 23

Chat with this insight

Recent Analyst Ratings for
$CYAD

$CYAD
SEC Filings

SEC Form 15F-12B filed by Celyad Oncology SA

SEC Form 6-K filed by Celyad Oncology SA

SEC Form 6-K filed by Celyad Oncology SA

$CYAD
Financials

Live finance-specific insights

$CYAD
Press Releases

Fastest customizable press release news feed in the world

$CYAD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Celyad Oncology reports full year 2022 financial results and recent business highlights

Celyad Oncology to announce full year 2022 financial results and host conference call

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Celyad Oncology announces receipt of Nasdaq delisting notice

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq

Celyad Oncology reports first quarter 2023 financial results and recent business highlights

Wells Fargo reiterated coverage on Celyad Oncology with a new price target

HC Wainwright & Co. reiterated coverage on Celyad Oncology with a new price target

HC Wainwright & Co. reiterated coverage on Celyad Oncology with a new price target

$CYAD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Celyad Oncology SA (Amendment)

SEC Form SC 13D/A filed by Celyad Oncology SA (Amendment)

SEC Form SC 13D filed by Celyad SA

$CYAD
Leadership Updates

Live Leadership Updates

Celyad Oncology appoints Georges Rawadi as its new CEO

Celyad Oncology Announces Leadership Updates

Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights

$CYAD
Market Insights

Live Market Insights

Celyad Oncology Announces Receipt Of Nasdaq Delisting Notice

12 Health Care Stocks Moving In Friday's Pre-Market Session

Celyad Oncology Has Approved Voluntary Delisting Of American Depositary Shares From NASDAQ, The Company Will Continue To Be Listed On Euronext Brussels

Celyad Oncology Names Company Insider Georges Rawadi as New CEO Effective March 23

Chat with this insight

Recent Analyst Ratings for $CYAD

$CYAD SEC Filings

SEC Form 15F-12B filed by Celyad Oncology SA

SEC Form 6-K filed by Celyad Oncology SA

SEC Form 6-K filed by Celyad Oncology SA

$CYAD Financials

Live finance-specific insights

$CYAD Press Releases

Fastest customizable press release news feed in the world

$CYAD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Celyad Oncology reports full year 2022 financial results and recent business highlights

Celyad Oncology to announce full year 2022 financial results and host conference call

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Celyad Oncology announces receipt of Nasdaq delisting notice

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq

Celyad Oncology reports first quarter 2023 financial results and recent business highlights

Wells Fargo reiterated coverage on Celyad Oncology with a new price target

HC Wainwright & Co. reiterated coverage on Celyad Oncology with a new price target

HC Wainwright & Co. reiterated coverage on Celyad Oncology with a new price target

$CYAD Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Celyad Oncology SA (Amendment)

SEC Form SC 13D/A filed by Celyad Oncology SA (Amendment)

SEC Form SC 13D filed by Celyad SA

$CYAD Leadership Updates

Live Leadership Updates

Celyad Oncology appoints Georges Rawadi as its new CEO

Celyad Oncology Announces Leadership Updates

Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights

$CYAD Market Insights

Live Market Insights

Celyad Oncology Announces Receipt Of Nasdaq Delisting Notice

12 Health Care Stocks Moving In Friday's Pre-Market Session

Celyad Oncology Has Approved Voluntary Delisting Of American Depositary Shares From NASDAQ, The Company Will Continue To Be Listed On Euronext Brussels

Recent Analyst Ratings for
$CYAD

$CYAD
SEC Filings

$CYAD
Financials

$CYAD
Press Releases

$CYAD
Analyst Ratings

$CYAD
Large Ownership Changes

$CYAD
Leadership Updates

$CYAD
Market Insights